OBJECTIVE: The authors conducted a prospective study of neurodegenerative and vascular dementia in Belgium. Strict diagnostic inclusion criteria were used to include well defined patients and controls. The results of apolipoprotein E (APOE) genotype effect on risk and clinical characteristics are presented. METHODS: APOE genotyping was performed in patients with probable Alzheimer's disease (AD) (n=504), frontotemporal dementia (FTD) (n=47), vascular dementia (VaD) (n=152), mixed dementia (n=132), mild cognitive impairment (MCI) (n=44), Parkinson's disease (PD) (n=30), dementia with Lewy bodies (DLB) (n=17), and multisystem atrophy (MSA)/progressive supranuclear palsy (PSP) (n=12). RESULTS: The APOE allele frequencies of this Belgian control population (epsilon 2: 6.9%; epsilon 3: 76.2%; epsilon 4: 16.9%) did not differ from those reported for other white populations. AD, MCI, and mixed dementia patients had higher APOE epsilon 4 (32.9%, 38.6%, and 28.4% respectively) and lower APOE epsilon 3 (62.2%, 53.4%, and 66.3%) frequencies compared with controls, whereas only AD and mixed dementia patients had lower APOE epsilon 2 frequencies (4.9% and 5.3%). Apart from a borderline significant different distribution of APOE allele frequencies in VaD patients compared with controls, no other differences were detected. The influence of APOE epsilon 4 on clinical features of dementia was limited to lower age at onset in AD patients and a less pronounced negative correlation between age at onset and number of epsilon 4 alleles in MCI and mixed dementia patients. CONCLUSIONS: This study confirmed the risk association between APOE epsilon 4 and AD. The observation that APOE epsilon 4 is associated with mixed dementia reflected the role of AD in the aetiopathogenesis of this condition. Although MCI is an aetiologically heterogeneous syndrome, the increased APOE epsilon 4 frequencies indicated that a large proportion of the MCI patients included in the study might be predisposed to develop AD.
OBJECTIVE: The authors conducted a prospective study of neurodegenerative and vascular dementia in Belgium. Strict diagnostic inclusion criteria were used to include well defined patients and controls. The results of apolipoprotein E (APOE) genotype effect on risk and clinical characteristics are presented. METHODS:APOE genotyping was performed in patients with probable Alzheimer's disease (AD) (n=504), frontotemporal dementia (FTD) (n=47), vascular dementia (VaD) (n=152), mixed dementia (n=132), mild cognitive impairment (MCI) (n=44), Parkinson's disease (PD) (n=30), dementia with Lewy bodies (DLB) (n=17), and multisystem atrophy (MSA)/progressive supranuclear palsy (PSP) (n=12). RESULTS: The APOE allele frequencies of this Belgian control population (epsilon 2: 6.9%; epsilon 3: 76.2%; epsilon 4: 16.9%) did not differ from those reported for other white populations. AD, MCI, and mixed dementiapatients had higher APOE epsilon 4 (32.9%, 38.6%, and 28.4% respectively) and lower APOE epsilon 3 (62.2%, 53.4%, and 66.3%) frequencies compared with controls, whereas only AD and mixed dementiapatients had lower APOE epsilon 2 frequencies (4.9% and 5.3%). Apart from a borderline significant different distribution of APOE allele frequencies in VaD patients compared with controls, no other differences were detected. The influence of APOE epsilon 4 on clinical features of dementia was limited to lower age at onset in ADpatients and a less pronounced negative correlation between age at onset and number of epsilon 4 alleles in MCI and mixed dementiapatients. CONCLUSIONS: This study confirmed the risk association between APOE epsilon 4 and AD. The observation that APOE epsilon 4 is associated with mixed dementia reflected the role of AD in the aetiopathogenesis of this condition. Although MCI is an aetiologically heterogeneous syndrome, the increased APOE epsilon 4 frequencies indicated that a large proportion of the MCI patients included in the study might be predisposed to develop AD.
Authors: Jessie Theuns; Nathalie Brouwers; Sebastiaan Engelborghs; Kristel Sleegers; Veerle Bogaerts; Ellen Corsmit; Tim De Pooter; Cornelia M van Duijn; Peter P De Deyn; Christine Van Broeckhoven Journal: Am J Hum Genet Date: 2006-04-10 Impact factor: 11.025
Authors: Natalie P Mota; Shizhong Han; Ilan Harpaz-Rotem; Paul Maruff; John H Krystal; Steven M Southwick; Joel Gelernter; Robert H Pietrzak Journal: Depress Anxiety Date: 2017-11-24 Impact factor: 6.505
Authors: Alexis Elbaz; Lorene M Nelson; Haydeh Payami; John P A Ioannidis; Brian K Fiske; Grazia Annesi; Andrea Carmine Belin; Stewart A Factor; Carlo Ferrarese; Georgios M Hadjigeorgiou; Donald S Higgins; Hideshi Kawakami; Rejko Krüger; Karen S Marder; Richard P Mayeux; George D Mellick; John G Nutt; Beate Ritz; Ali Samii; Caroline M Tanner; Christine Van Broeckhoven; Stephen K Van Den Eeden; Karin Wirdefeldt; Cyrus P Zabetian; Marie Dehem; Jennifer S Montimurro; Audrey Southwick; Richard M Myers; Thomas A Trikalinos Journal: Lancet Neurol Date: 2006-11 Impact factor: 44.182
Authors: Yi-Fang Chuang; Kathleen M Hayden; Maria C Norton; Joann Tschanz; John C S Breitner; Kathleen A Welsh-Bohmer; Peter P Zandi Journal: Dement Geriatr Cogn Disord Date: 2010-04-06 Impact factor: 2.959